Aphria Inc. reported earnings results for the second quarter ended November 30, 2016. For the quarter, the company's revenue was CAD 2,096,975 compared to CAD 5,226,589 a year ago. The increase in revenue for the quarter was primarily a result of increased average selling price per gram (or gram equivalents) sold. Earnings before tax was CAD 945,678 compared to loss before tax of CAD 431,098 a year ago. The increased pre-tax profitability is attributed to strong growth in the average selling price per kilogram (or kilogram equivalent) and very strong new patient registrations in the quarter. EBITDA was CAD 1,198,620 compared to CAD 4,108 a year ago. The EBITDA growth reflects the Company's continued focus on low cost producer status and industry leading patient care, quarter over quarter. Net income for the three months ended November 30, 2016 was CAD 945,678 or CAD 0.01 per share as opposed to a net loss of CAD 431,098 or CAD 0.01 per share in the same quarter in the previous year and an income before tax of CAD 895,269 or CAD 0.01 per share in the previous quarter.